Chronic Myeloproliferative Disorders Completed Phase 1 Trials for Rituximab (DB00073)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00080925T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesTreatment